Figure 7
From: MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma
A combined model with both miR-150 and mi155 predicts progression-free survival in primary cutaneous marginal zone B-cell lymphomas. (a) Cases were stratified into three groups: (1) those with low-expression levels of miR-150 and miR-155; (2) patients with low-expression levels of either miR-150 or miR-155; (3) patients with high levels of expression of both miRNAs. Group 1 patients had a poorer outcome than those in groups 2 and 3 (left). (b) The effect of miR-150 and miR-155 on the progression-free survival is dependent on lymphoma type. Stratifying patients by PCFCL and primary cutaneous marginal zone B-cell lymphomas revealed that the loss of miR-150 and miR-155 identified patients with poor prognosis in the primary cutaneous marginal zone B-cell lymphomas group (P<0.01), but not in the PCFCL group (P>0.05).
